Cryptococcus and Phagocytes: Complex Interactions That Influence Disease Outcome

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2016 Feb 24

PMID 26903984

Citations 55

Authors

Chrissy M Leopold Wager

Camaron R Hole

Karen L Wozniak

Floyd L Wormley Jr

Affiliations

Soon will be listed here.

Abstract

Cryptococcus neoformans and C. gattii are fungal pathogens that cause life-threatening disease. These fungi commonly enter their host via inhalation into the lungs where they encounter resident phagocytes, including macrophages and dendritic cells, whose response has a pronounced impact on the outcome of disease. Cryptococcus has complex interactions with the resident and infiltrating innate immune cells that, ideally, result in destruction of the yeast. These phagocytic cells have pattern recognition receptors that allow recognition of specific cryptococcal cell wall and capsule components. However, Cryptococcus possesses several virulence factors including a polysaccharide capsule, melanin production and secretion of various enzymes that aid in evasion of the immune system or enhance its ability to thrive within the phagocyte. This review focuses on the intricate interactions between the cryptococci and innate phagocytic cells including discussion of manipulation and evasion strategies used by Cryptococcus, anti-cryptococcal responses by the phagocytes and approaches for targeting phagocytes for the development of novel immunotherapeutics.

Citing Articles

Pulmonary granuloma formation during latent infection in C3HeB/FeJ mice involves progression through three immunological phases.

Betancourt J, Ding M, Yoder J, Mutyaba I, Atkins H, De la Cruz G mBio. 2025; 16(2):e0361024.

PMID: 39807873 PMC: 11796415. DOI: 10.1128/mbio.03610-24.

Effect of insertion of intein to Cryptococcus amylolentus, a nonpathogenic fungus closely related to causative agents of cryptococcosis.

Tharappel A, Li Z, Li H Microb Pathog. 2024; 199:107267.

PMID: 39736341 PMC: 11863799. DOI: 10.1016/j.micpath.2024.107267.

Common virulence factors between and : Recognition of Hsp60 and Enolase by CR3 and plasmin receptors in host cells.

de Matos Silva S, Echeverri C, Mendes-Giannini M, Fusco-Almeida A, Gonzalez A Curr Res Microb Sci. 2024; 7:100246.

PMID: 39022313 PMC: 11253281. DOI: 10.1016/j.crmicr.2024.100246.

Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines.

Wang R, Oliveira L, Hester M, Carlson D, Christensen D, Specht C PLoS Pathog. 2024; 20(7):e1012220.

PMID: 38976694 PMC: 11257399. DOI: 10.1371/journal.ppat.1012220.

Global trends in and its interactions with the host immune system: a bibliometric analysis.

Tang S, Hao R, Liu X, He H, Tian Y, Jing T Front Immunol. 2024; 15:1397338.

PMID: 38774865 PMC: 11106374. DOI: 10.3389/fimmu.2024.1397338.

References

Chinen T, Qureshi M, Koguchi Y, Kawakami K . Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages. Clin Exp Immunol. 1999; 115(3):491-7. PMC: 1905260. DOI: 10.1046/j.1365-2249.1999.00822.x. View

Liu L, Tewari R, Williamson P . Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages. Infect Immun. 1999; 67(11):6034-9. PMC: 96990. DOI: 10.1128/IAI.67.11.6034-6039.1999. View

Bogdan C, Rollinghoff M, Diefenbach A . Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol. 2000; 12(1):64-76. DOI: 10.1016/s0952-7915(99)00052-7. View

Saag M, Graybill R, Larsen R, Pappas P, Perfect J, Powderly W . Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4):710-8. DOI: 10.1086/313757. View

Bauman S, Nichols K, Murphy J . Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol. 2000; 165(1):158-67. DOI: 10.4049/jimmunol.165.1.158. View

Mambula S, Simons E, Hastey R, Selsted M, Levitz S . Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect Immun. 2000; 68(11):6257-64. PMC: 97707. DOI: 10.1128/IAI.68.11.6257-6264.2000. View

Aguirre K, Gibson G . Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Med Mycol. 2000; 38(5):343-53. DOI: 10.1080/mmy.38.5.343.353. View

Shoham S, Huang C, Chen J, Golenbock D, Levitz S . Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001; 166(7):4620-6. DOI: 10.4049/jimmunol.166.7.4620. View

Husain S, Wagener M, Singh N . Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis. 2001; 7(3):375-81. PMC: 2631789. DOI: 10.3201/eid0703.010302. View

10.

Coenjaerts F, Walenkamp A, Mwinzi P, Scharringa J, Dekker H, Van Strijp J . Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J Immunol. 2001; 167(7):3988-95. DOI: 10.4049/jimmunol.167.7.3988. View

11.

Tucker S, Casadevall A . Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci U S A. 2002; 99(5):3165-70. PMC: 122490. DOI: 10.1073/pnas.052702799. View

12.

Mansour M, Schlesinger L, Levitz S . Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J Immunol. 2002; 168(6):2872-9. DOI: 10.4049/jimmunol.168.6.2872. View

13.

Rivera J, Mukherjee J, Weiss L, Casadevall A . Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J Immunol. 2002; 168(7):3419-27. DOI: 10.4049/jimmunol.168.7.3419. View

14.

Hu X, Herrero C, Li W, Antoniv T, Falck-Pedersen E, Koch A . Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol. 2002; 3(9):859-66. DOI: 10.1038/ni828. View

15.

Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F . Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis. 2002; 186(4):522-30. DOI: 10.1086/341564. View

16.

Syme R, Spurrell J, Amankwah E, Green F, Mody C . Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect Immun. 2002; 70(11):5972-81. PMC: 130340. DOI: 10.1128/IAI.70.11.5972-5981.2002. View

17.

Wright L, Bubb W, Davidson J, Santangelo R, Krockenberger M, Himmelreich U . Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. Microbes Infect. 2002; 4(14):1427-38. DOI: 10.1016/s1286-4579(02)00024-2. View

18.

Bauman S, Huffnagle G, Murphy J . Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response. Infect Immun. 2002; 71(1):68-74. PMC: 143367. DOI: 10.1128/IAI.71.1.68-74.2003. View

19.

Mednick A, Feldmesser M, Rivera J, Casadevall A . Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis. Eur J Immunol. 2003; 33(6):1744-53. DOI: 10.1002/eji.200323626. View

20.

Vecchiarelli A, Pietrella D, Lupo P, Bistoni F, McFadden D, Casadevall A . The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukoc Biol. 2003; 74(3):370-8. DOI: 10.1189/jlb.1002476. View